Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PML_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PML_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PML_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PML_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PML_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004586234 | Thyroid | ATC | positive regulation of proteolysis | 202/6293 | 372/18723 | 1.07e-16 | 9.42e-15 | 202 |
GO:004477219 | Thyroid | ATC | mitotic cell cycle phase transition | 223/6293 | 424/18723 | 3.46e-16 | 2.88e-14 | 223 |
GO:000734622 | Thyroid | ATC | regulation of mitotic cell cycle | 236/6293 | 457/18723 | 7.58e-16 | 5.92e-14 | 236 |
GO:003629328 | Thyroid | ATC | response to decreased oxygen levels | 177/6293 | 322/18723 | 1.81e-15 | 1.32e-13 | 177 |
GO:000166628 | Thyroid | ATC | response to hypoxia | 169/6293 | 307/18723 | 6.58e-15 | 4.12e-13 | 169 |
GO:001905835 | Thyroid | ATC | viral life cycle | 173/6293 | 317/18723 | 9.22e-15 | 5.50e-13 | 173 |
GO:007233135 | Thyroid | ATC | signal transduction by p53 class mediator | 102/6293 | 163/18723 | 3.16e-14 | 1.75e-12 | 102 |
GO:001604927 | Thyroid | ATC | cell growth | 241/6293 | 482/18723 | 4.27e-14 | 2.35e-12 | 241 |
GO:003459934 | Thyroid | ATC | cellular response to oxidative stress | 158/6293 | 288/18723 | 7.35e-14 | 3.94e-12 | 158 |
GO:007155925 | Thyroid | ATC | response to transforming growth factor beta | 142/6293 | 256/18723 | 4.30e-13 | 1.94e-11 | 142 |
GO:001820516 | Thyroid | ATC | peptidyl-lysine modification | 193/6293 | 376/18723 | 6.92e-13 | 3.06e-11 | 193 |
GO:0097191210 | Thyroid | ATC | extrinsic apoptotic signaling pathway | 125/6293 | 219/18723 | 7.19e-13 | 3.16e-11 | 125 |
GO:007156026 | Thyroid | ATC | cellular response to transforming growth factor beta stimulus | 137/6293 | 250/18723 | 3.69e-12 | 1.49e-10 | 137 |
GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
GO:004518532 | Thyroid | ATC | maintenance of protein location | 64/6293 | 94/18723 | 8.44e-12 | 3.16e-10 | 64 |
GO:004440334 | Thyroid | ATC | biological process involved in symbiotic interaction | 153/6293 | 290/18723 | 1.12e-11 | 4.12e-10 | 153 |
GO:190199015 | Thyroid | ATC | regulation of mitotic cell cycle phase transition | 156/6293 | 299/18723 | 2.19e-11 | 7.80e-10 | 156 |
GO:000717924 | Thyroid | ATC | transforming growth factor beta receptor signaling pathway | 112/6293 | 198/18723 | 2.42e-11 | 8.44e-10 | 112 |
GO:200102026 | Thyroid | ATC | regulation of response to DNA damage stimulus | 121/6293 | 219/18723 | 3.22e-11 | 1.08e-09 | 121 |
GO:000166731 | Thyroid | ATC | ameboidal-type cell migration | 228/6293 | 475/18723 | 3.72e-11 | 1.22e-09 | 228 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PML | SNV | Missense_Mutation | novel | c.1022C>T | p.Ser341Leu | p.S341L | P29590 | protein_coding | deleterious(0.03) | probably_damaging(0.983) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PML | SNV | Missense_Mutation | | c.1228N>G | p.Pro410Ala | p.P410A | P29590 | protein_coding | tolerated(0.06) | probably_damaging(0.95) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PML | deletion | Frame_Shift_Del | | c.208delN | p.Leu70CysfsTer28 | p.L70Cfs*28 | P29590 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
PML | SNV | Missense_Mutation | rs769540520 | c.2221N>T | p.Arg741Cys | p.R741C | P29590 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PML | SNV | Missense_Mutation | rs765869727 | c.973C>T | p.Arg325Cys | p.R325C | P29590 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PML | SNV | Missense_Mutation | | c.895G>C | p.Glu299Gln | p.E299Q | P29590 | protein_coding | tolerated(0.23) | benign(0.3) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
PML | SNV | Missense_Mutation | | c.1702N>A | p.Glu568Lys | p.E568K | P29590 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | | c.502N>A | p.Glu168Lys | p.E168K | P29590 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | novel | c.1015N>A | p.Tyr339Asn | p.Y339N | P29590 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA43-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PML | SNV | Missense_Mutation | rs745678082 | c.2218N>A | p.Glu740Lys | p.E740K | P29590 | protein_coding | tolerated(0.2) | benign(0.007) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | GEMTUZUMAB OZOGAMICIN | | 15187030 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TRETINOIN | TRETINOIN | 21505136,8674046,21613260,23670176,11704842,30289902 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | arsenic trioxide | | 24433361 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | tretinoin | TRETINOIN | |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TAMIBAROTENE | TAMIBAROTENE | 30289902 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | TAZAROTENE | TAZAROTENE | 16939905 |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | Tretinoin | TRETINOIN | |
5371 | PML | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUG RESISTANCE | | ARSENIC TRIOXIDE | | 26537301,11704842 |